Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19637201 | 0.93 | KRAS (0.61) | KRASSOS1 | |
| SCHEMBL19637069 | 0.92 | KRAS (0.74) | KRASSOS1 | |
| SCHEMBL19959171 | 0.85 | KRAS (0.65) | KRAS | |
| SCHEMBL19959203 | 0.85 | KRAS (0.84) | KRAS | |
| SCHEMBL21912118 | 0.84 | KRAS (0.63) | KRAS | |
| SCHEMBL25021352 | 0.82 | KRAS (0.63) | KRAS | |
| SCHEMBL19948175 | 0.81 | KRAS (0.60) | KRAS | |
| SCHEMBL19616813 | 0.81 | KRAS (0.60) | KRAS | |
| SCHEMBL19959218 | 0.81 | KRAS (0.85) | KRAS | |
| SCHEMBL22440393 | 0.80 | KRAS (0.60) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373999-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20180072723-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2018-03-15 | — | — | US | disclosed |
| WO-2017201161-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072723-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885SOS1 94/4885 |
| US-20230373999-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885SOS1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.